Caricamento azienda
Just reported
From Generate Biomedicines's results release of 12 novembre 2026; its quarterly report has since been filed.
Actual
4,2M USD
-56% y/y
-33% q/q
Guided
—
No guide given
Actual
-0,68 USD
Guided
—
No guide given
Actual
-91,5M USD
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Generate Biomedicines is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B USDA+
EXELExelixis, Inc.16,8B USDA+
JAZZJazz Pharmaceuticals plc15,5B USDA
TECHBIO-Techne Corp11,4B USDA+
HALOHalozyme Therapeutics, Inc.11,4B USDA+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 ott 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 ott 2026CAGraded C, now ALe quote di ricavo sono stime per six months ended June 30, 2026, non cifre tratte da un documento depositato.
GB-0895
An experimental antibody that blocks thymic stromal lymphopoietin, an immune-system signal. It is being tested in late-stage trials for severe asthma.
GB-4362
An experimental medicine designed to neutralize monomethyl auristatin E, a drug used in some cancer treatments. It has entered human testing.
GB-5267
An experimental cancer treatment using modified chimeric antigen receptor T cells, immune cells altered to recognize and attack cancer. It is being developed with Roswell Park Comprehensive Cancer Center.
Generate Biomedicines uses artificial intelligence and laboratory experiments to design and test proteins that could become medicines. Its most advanced candidate is being tested in severe asthma, and it is also developing treatments for other diseases. It has no medicines approved for sale; its current revenue comes from research collaborations with drug companies.
Costruito dai documenti depositati da Generate Biomedicines, Inc. presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.
Generate Biomedicines earns research payments from drug companies to design protein medicines, while developing its own experimental treatments for severe asthma and cancer.
Not rated
La fascia sotto il prezzo mostra il voto in ogni data, calcolato solo sui documenti già pubblici in quel momento.
Non c’è ancora uno storico dei voti da tracciare per Generate Biomedicines, Inc.. Il voto trimestrale è ricostruito solo dai documenti pubblici all’epoca, e questa azienda non ne ha ancora depositati abbastanza per valutare un solo trimestre.
